PTPN11 and cancer: Inhibition of SHP2 combined with inhibitors of KRASG12C, RAF, or MEK has been shown to generate deep growth suppression in multiple preclinical cancer models, and these underlying mechanisms involve RTK feedback blockade by SHP2 inhibitors.